Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022672 (
acute tubular necrosis
)
2,175
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Apoptosis of tubular epithelial cells is a hallmark of acute kidney injury (AKI), but the cellular events preceding apoptosis in this setting are incompletely understood. Because matrix metalloproteinase 9 (MMP9) degrades matrix components involved in cell survival, we studied the role of
MMP9
in AKI. In the mouse model of folic acid-induced AKI, we observed a marked increase of
MMP9
activity in the S3 segment of the proximal tubule (S3PT), correlating with the apoptotic phase.
MMP9
deficiency increased apoptosis and the severity of renal lesions and substantially delayed recovery of renal function.
MMP9
-/- mice exhibited significant apoptosis in the S3PT and the intercalated cells of the collecting duct (I-CD), whereas wild-type mice exhibited none in these segments. Stem cell factor (SCF), an
MMP9
substrate, was identified in the S3PT, and its receptor, c-Kit, was expressed in both the S3PT and I-CD.
MMP9
released the soluble form of SCF (sSCF) from kidney cells in vivo and in vitro. In addition, SCF inhibited apoptosis of tubular cells in vitro, rescued
MMP9
-/- S3PT and I-CD from apoptosis in vivo, and improved renal function. An ischemia-reperfusion model of AKI produced similar results. In patients with AKI, urinary sSCF increased with
acute tubular necrosis
but not with prerenal azotemia. In conclusion, these data show that
MMP9
protects the S3 segment of the proximal tubule and the I-CD from apoptosis in AKI, most likely by releasing sSCF.
...
PMID:MMP9 and SCF protect from apoptosis in acute kidney injury. 1932 63